UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4‐infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir

Journal of viral hepatitis, 2018-09, Vol.25 (9), p.1078-1088

2018

Volltextzugriff (PDF)

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)

Journal of viral hepatitis, 2018-02, Vol.25 (2), p.118-125

2018

Volltextzugriff (PDF)

Next steps in the footprint project: A feasibility study of installing solar panels on Bath Abbey

Energy science & engineering, 2022-03, Vol.10 (3), p.892-902

2022

Volltextzugriff (PDF)

867 IN VITRO COMBINATORY EFFECT OF HCV NS3/4A PROTEASE INHIBITOR ABT-450, NS5A INHIBITOR ABT-267, AND NON-NUCLEOSIDE NS5B POLYMERASE INHIBITOR ABT-333

Journal of hepatology, 2012-04, Vol.56, p.S338-S338

2012

Volltextzugriff (PDF)

Detailed study of HEDTA’s chemodynamics upon gamma-radiolysis in a simulated, mixed waste

Journal of radioanalytical and nuclear chemistry, 2008-07, Vol.277 (1), p.5-10

2008

Volltextzugriff (PDF)

The periodontal disease problem. A comparison between industrialised and developing countries

International dental journal, 1998-06, Vol.48 (S3), p.221-232

Pilot, T.

1998

Volltextzugriff (PDF)

Introduction - ART from a global perspective

Community dentistry and oral epidemiology, 1999-12, Vol.27 (6), p.421-422

Pilot, Taco

1999

Volltextzugriff (PDF)

Caspase 8-dependent inhibition of necroptosis prevents plaque necrotic core formation

Atherosclerosis, 2023-08, Vol.379, p.S8-S9

2023

Volltextzugriff (PDF)

Prevalence of TT Virus Infection in US Blood Donors and Populations at Risk for Acquiring Parenterally Transmitted Viruses

The Journal of infectious diseases, 1999-05, Vol.179 (5), p.1242-1244

1999

Volltextzugriff (PDF)

Pooled resistance analysis in HCV genotype 1–6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials

Journal of hepatology, 2017, Vol.66 (1), p.S500-S500

2017

Volltextzugriff (PDF)

Efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir in non-cirrhotic Asian patients with genotype 1b chronic hepatitis C virus infection: ONYX-I post-treatment week 24 results

Journal of hepatology, 2017, Vol.66 (1), p.S532-S532

2017

Volltextzugriff (PDF)

Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypes

Journal of hepatology, 2017, Vol.66 (1), p.S324-S324

2017

Volltextzugriff (PDF)

Resistance analysis in the MAGELLAN-1 Study (Part 2): glecaprevir/pibrentasvir therapy in HCV-infected patients who had failed prior DAA regimens containing NS3/4A protease and/or NS5A inhibitors

Journal of hepatology, 2017, Vol.66 (1), p.S708-S709

2017

Volltextzugriff (PDF)

EXPEDITION-I: efficacy and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis

Journal of hepatology, 2017, Vol.66 (1), p.S3-S4

2017

Volltextzugriff (PDF)

High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis

Journal of hepatology, 2017, Vol.66 (1), p.S721-S721

2017

Volltextzugriff (PDF)

CERTAIN-1: efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

Journal of hepatology, 2017, Vol.66 (1), p.S527-S527

2017

Volltextzugriff (PDF)

Effect of Baseline Resistance-Associated Variants on SVR with the 3D Regimen with and without RBV in GT1A and GT1B-Infected Patients

Journal of hepatology, 2016, Vol.64 (2), p.S214-S214

2016

Volltextzugriff (PDF)

Analysis of HCV Genotype 2 and 3 Variants in Patients Treated with Combination Therapy of Next Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530

Journal of hepatology, 2016, Vol.64 (2), p.S409-S410

2016

Volltextzugriff (PDF)

High SVR Rates in Patients with Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis with Ombitasvir/Paritaprevir/Ritonavir Co-Administered with Ribavirin (AGATE-I)

Journal of hepatology, 2016, Vol.64 (2), p.S827-S827

2016

Volltextzugriff (PDF)

Ombitasvir/Paritaprevir/R, Dasabuvir, and Sofosbuvir Treatment of Patients with HCV Genotype-Infection who Failed a Prior Course of DAA Therapy: The Quartz-I Study

Journal of hepatology, 2016, Vol.64 (2), p.S767-S768

2016

Volltextzugriff (PDF)

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection with and without cirrhosis

Journal of hepatology, 2017, Vol.66 (1), p.S528-S528

2017

Volltextzugriff (PDF)

MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure

Journal of hepatology, 2017, Vol.66 (1), p.S83-S84

2017

Volltextzugriff (PDF)

O057 : Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens

Journal of hepatology, 2015-04, Vol.62, p.S220-S220

2015

Volltextzugriff (PDF)

P1345 : A randomized, open-label study to evaluate efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis

Journal of hepatology, 2015-04, Vol.62, p.S861-S861

2015

Volltextzugriff (PDF)

P07.02 Enhanced glycolysis in glioblastomas is associated with tumor cells migration

Neuro-oncology (Charlottesville, Va.), 2019-09, Vol.21 (Supplement_3), p.iii36-iii37

2019

Volltextzugriff (PDF)

1 – 25 von 2.189

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.514)
Mit Volltextzugriff
(1.644)

Publikationsform

8 weitere anzeigen...

Weniger anzeigen...

Sprache

7 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4‐infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)

Next steps in the footprint project: A feasibility study of installing solar panels on Bath Abbey

867 IN VITRO COMBINATORY EFFECT OF HCV NS3/4A PROTEASE INHIBITOR ABT-450, NS5A INHIBITOR ABT-267, AND NON-NUCLEOSIDE NS5B POLYMERASE INHIBITOR ABT-333

Detailed study of HEDTA’s chemodynamics upon gamma-radiolysis in a simulated, mixed waste

The periodontal disease problem. A comparison between industrialised and developing countries

Introduction - ART from a global perspective

Caspase 8-dependent inhibition of necroptosis prevents plaque necrotic core formation

Prevalence of TT Virus Infection in US Blood Donors and Populations at Risk for Acquiring Parenterally Transmitted Viruses

Pooled resistance analysis in HCV genotype 1–6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials

Efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir in non-cirrhotic Asian patients with genotype 1b chronic hepatitis C virus infection: ONYX-I post-treatment week 24 results

Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypes

Resistance analysis in the MAGELLAN-1 Study (Part 2): glecaprevir/pibrentasvir therapy in HCV-infected patients who had failed prior DAA regimens containing NS3/4A protease and/or NS5A inhibitors

EXPEDITION-I: efficacy and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis

High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis

CERTAIN-1: efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

Effect of Baseline Resistance-Associated Variants on SVR with the 3D Regimen with and without RBV in GT1A and GT1B-Infected Patients

Analysis of HCV Genotype 2 and 3 Variants in Patients Treated with Combination Therapy of Next Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530

High SVR Rates in Patients with Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis with Ombitasvir/Paritaprevir/Ritonavir Co-Administered with Ribavirin (AGATE-I)

Ombitasvir/Paritaprevir/R, Dasabuvir, and Sofosbuvir Treatment of Patients with HCV Genotype-Infection who Failed a Prior Course of DAA Therapy: The Quartz-I Study

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection with and without cirrhosis

MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure

O057 : Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens

P1345 : A randomized, open-label study to evaluate efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis

P07.02 Enhanced glycolysis in glioblastomas is associated with tumor cells migration

Suchergebnisse filtern